SS is identified by B‐cell hyperactivity characterized by hypergammaglobulinemia and a variety of autoantibodies, with B‐cell activating factor (BAFF; also known as BLyS), a B‐cell survival factor, playing a significant role.1 Here, TNFSF13B is linked to synovial sarcoma.